Regulus Therapeutics Inc. (RGLS)
$
1.75
+0.02 (1.14%)
Key metrics
Financial statements
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the discovery and development of drugs that target microRNAs to treat a variety of diseases in the United States. The gross profit ratio is 0.00 reflecting the efficiency of the company's production and sales operations. Its product candidates include RG-012, an anti-miR targeting miR-21, which is currently in a Phase II clinical trial for the treatment of Alport syndrome, a serious kidney disease. Additionally, RGLS8429, an anti-miR targeting miR-17, is undergoing a Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The weighted average number of shares outstanding is 56,346,033.00 highlighting the company's shareholder base. Furthermore, the EBITDA ratio is 0.00 indicating the company's operational efficiency. The company recorded an operating income of -$50,040,000.00 reflecting its earnings from core operations. Meanwhile, the net total of other income and expenses is $3,683,000.00 showcasing non-core financial activities. Regulus Therapeutics is also advancing a pipeline of preclinical drug products, aiming for target organ-selective delivery strategies. Incorporated in 2007 and headquartered in San Diego, California, it is poised for significant contributions to the biopharmaceutical landscape. The stock is affordable at $1.80 making it suitable for budget-conscious investors. With a low average trading volume of 1,079,156.00 the stock indicates lower market activity. With a market capitalization of $115,925,948.00 the company is classified as a small-cap player. Regulus Therapeutics is a key player in the biopharmaceutical industry, contributing significantly to the overall market landscape. It belongs to the healthcare sector, driving innovation and growth in the field. As the company continues to develop its promising drug candidates and preclinical offerings, it reinforces its commitment to addressing unmet medical needs while appealing to a diverse range of investors and stakeholders.
Is Regulus Therapeutics Inc. (RGLS) a good investment?
Investing in Regulus Therapeutics Inc. (RGLS) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Regulus Therapeutics Inc. (RGLS)'s stock forecast?
Analysts predict Regulus Therapeutics Inc. stock to fluctuate between $0.83 (low) and $2.90 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Regulus Therapeutics Inc.'s market capitalization?
As of 2025-04-02, Regulus Therapeutics Inc.'s market cap is $115,925,948, based on 66,243,399 outstanding shares.
How does Regulus Therapeutics Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Regulus Therapeutics Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Regulus Therapeutics Inc. (RGLS) stock?
To buy Regulus Therapeutics Inc. (RGLS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for RGLS. Place an order (Market, Limit, etc.).
What is the best time to invest in Regulus Therapeutics Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Regulus Therapeutics Inc. stock ever split?
Regulus Therapeutics Inc.'s last stock split was 1:10 on 2022-06-29.
How did Regulus Therapeutics Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$0.82 | Growth: -48.10%.
Where can I find Regulus Therapeutics Inc.'s investor relations reports?
Visit https://www.regulusrx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Regulus Therapeutics Inc.?
You can explore historical data from here
What is the all-time high and low for Regulus Therapeutics Inc. stock?
All-time high: $23.20 (2021-03-12) | All-time low: $0.76 (2023-03-20).
What are the key trends affecting Regulus Therapeutics Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Regulus (RGLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
prnewswire.com
SAN DIEGO , Feb. 4, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that members of the management team will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11 th at 2:40 p.m. ET. The live event and replay of the presentation will be available under "Events and Presentations" through the investor relations section of the Company's website at https://ir.regulusrx.com/events and archived for 90 days following the presentation date.
prnewswire.com
Topline data from an interim analysis of the fourth cohort of its Phase 1b Multiple-Ascending Dose (MAD) clinical trial showed continued mechanistic dose response Exploratory results of imaging-based biomarkers continued to show reduction in height-adjusted total kidney volume (htTKV) growth rate Successful End-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA) with agreement on key components of a Phase 3 single pivotal trial for potential Accelerated Approval Company to hold conference call at 8:30 a.m. ET today SAN DIEGO , Jan. 29, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced positive clinical and regulatory updates from its ADPKD program.
prnewswire.com
SAN DIEGO , Nov. 26, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company will participate in the following investor conferences: Evercore 7th Annual HealthCONx Conference: Fireside chat on Tuesday, December 3, 2024, at 3:50 p.m. ET Piper Sandler 36th Annual Healthcare Conference: Presentation on Wednesday, December 4, 2024, at 11:10 a.m.
prnewswire.com
Completed enrollment in the fourth cohort of the Phase 1b multiple-ascending dose (MAD) clinical trial of RGLS8429 for the treatment of autosomal dominant polycystic kidney disease (ADPKD) Presented a poster highlighting data from the ongoing MAD study of RGLS8429 in ADPKD at American Society of Nephrology (ASN) Kidney Week On track for an End-of-Phase 1 meeting by year-end Ended third quarter 2024 with cash, cash equivalents, and investments of $87.3 million; Cash runway into H1 2026 SAN DIEGO , Nov. 7, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results and provided a corporate update for the third quarter ended September 30, 2024. "We have remained focused on rapidly progressing RGLS8429 for the potential treatment of ADPKD and were pleased to announce the completion of enrollment in our fourth and final cohort of the Phase 1b MAD study last month.
prnewswire.com
SAN DIEGO , Oct. 8, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced it has completed enrollment of 26 patients in the fourth cohort in the Phase 1b MAD study of RGLS8429 for the treatment of ADPKD. "The completion of enrollment of our final cohort marks an important milestone as we near the end of our Phase 1b study.
prnewswire.com
SAN DIEGO , Aug. 28, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company will participate in the following investor conferences: Wells Fargo Healthcare Conference: Fireside chat on Wednesday, September 4, 2024, at 2:15 p.m. ET H.C. Wainwright 26th Annual Global Investment Conference: Fireside chat on Monday, September 9, 2024, at 10:00 a.m.
prnewswire.com
Announced positive topline data from the third cohort of patients in the Phase 1b MAD study of RGLS8429 in autosomal dominant polycystic kidney disease (ADPKD) On track for an End-Of-Phase 1 meeting by year-end Appointed Rekha Garg, M.D., M.S., to Chief Medical Officer Ended second quarter 2024 with cash, cash equivalents, and investments of $95.9 million; Cash runway into H1 2026 SAN DIEGO , Aug. 8, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update.
prnewswire.com
SAN DIEGO , Aug. 6, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that members of the management team will present at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13 th at 8:30 a.m. ET. A replay of the live presentation will be available under "Events and Presentations" through the investor relations section of the Company's website at https://ir.regulusrx.com/events and archived for 90 days following the presentation date.
prnewswire.com
SAN DIEGO , July 9, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company will participate in the following investor conferences: H.C. Wainwright Third Annual Kidney Virtual Conference: Fireside chat on Monday, July 15, 2024, at 10:30 a.m.
See all news
